KeithShulmanMD

Oncology • Rolling Meadows, IL

Physician

Join to view full profile

Dr. Shulman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shulman's full profile

Already have an account?

Office
2000 Golf Rd
Rolling Meadows, IL 60008
Phone+1 847-871-1800

Fax+1 847-871-1811
Is this information wrong?

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1987 - 1989
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 1984 - 1985
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1983 - 1984
Washington University in St. Louis School of MedicineClass of 1983

Certifications & Licensure

IL State Medical License 1984 - 2026

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Home-Based Programs for Improving Sleep in Cancer Survivors Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Gastroparesis in a patient with Parkinson's disease.
Maheep Sangha, Alok Arora, Keith Shulman> ;British Journal of Hospital Medicine. 2016 May 11
7 citations
Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days
Michael B. Sawyer, Mark J. Ratain, D. Bertucci, Robert P. Smith, Richard L. Schilsky, Nicholas J. Vogelzang, Keith L. Shulman, Edwin C. Douglass, Gini F. Fleming> ;Journal of Clinical Oncology. 2003 May 1
15 citations
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study
Sridhar Mani, John W. Kugler, David F. Sciortino, Juan C. Garcia, Rafat Ansari, Rod A. Humerickhouse, Fabrizio Michelassi, Mitchell C. Posner, K. L. Shulman, Richard L...> ;Annals of Oncology. 1998 Sep 1
10 citations
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Keith L. Shulman, Walter M. Stadler, Nicholas J. Vogelzang> ;Urology. 1996 Feb 1
24 citations
Adverse reactions to intravenous contrast media in patients treated with interleukin-2
Keith L. Shulman, John A. Thompson, M C Benyunes, Thomas C. Winter, Alexander Fefer> ;Journal of Immunotherapy With Emphasis on Tumor Immunology. 1993 Apr 1
52 citations
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
John A. Thompson, Keith L. Shulman, M C Benyunes, Cathy G. Lindgren, Carolyn Collins, Paul H. Lange, Lynn A. Benz, Alexander Fefer, William H. Bush> ;Journal of Clinical Oncology. 1992 Jun 1
Join now to see all